10-K/A: SBC Medical Group Holdings Files Amendment to 2024 Annual Report, Updates Executive Roles and Agreements

SBC Medical Group Holdings files an amendment to its 2024 annual report, primarily to restate information regarding related person transactions and director independence, and to include updated certifications and executive employment agreements.

Summary

• SBC Medical Group Holdings Incorporated filed Amendment No.
• 2 on Form 10-K/A to further amend the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• The amendment restates Item 13 of Part III of the 2024 10-K regarding certain relationships and related transactions, and director independence.
• It also updates the exhibit list in Item 15 of Part IV to include new certifications by the principal executive officer and principal financial officer under Section 302 of the Sarbanes-Oxley Act of 2002, as well as two employment agreements with executive officers.
• The company was originally incorporated as Pono Capital Two, Inc., a special purpose acquisition company, on February 12, 2021.
• On September 17, 2024, the closing of the merger and business combination took place, and Pono changed its name to SBC Medical Group Holdings Incorporated.
• The amendment includes details of related party transactions, including those with Medical Corporations (MCs) in Japan, where relatives of the CEO are members.
• In January 2024, Legacy SBC acquired 353,600 shares of common stock of Waqoo, a related-party company listed on the Tokyo Stock Exchange, with a fair value of $5,565,938 through a share exchange agreement.
• The company sold its subsidiaries, Kijima and Skynet, to entities owned by the CEO for cash consideration of one Japanese Yen ($0) for Kijima and $446,460 for Skynet.
• The company has Partner Doctor Independence Support Program Agreements (PDISPA) with each of the MCs, with a term of 5 years from September 1, 2021, to August 31, 2026.
• The company has amended and renewed the SBC Operating Agreement (SBCOA) with each MC, effective from April 1, 2025, with a term from April 1, 2025 to March 31, 2026.
• The Board of Directors has determined that each of Ken Edahiro, Mike Sayama, and Fumitoshi Fujiwara satisfy the applicable independence standards established by the SEC and the Nasdaq Listing Rules.
• Yuya Yoshida was appointed as the Chief Financial Officer of the Company as well as the Chief Operating Officer with an annual base salary of JPY44,000,000.
• Miki Yamazaki was appointed as the Chief Strategy Officer of the Company with an annual base salary of JPY 38,000,000.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily focused on providing factual updates and disclosures. The high number of related party transactions and the sale of subsidiaries to the CEO for nominal consideration are potential areas of concern.

Positives

• The company is proactively addressing SEC requirements by filing amendments and updating disclosures.
• The company is renewing agreements with MCs to facilitate the establishment of new clinics.
• The company is providing indemnification and insurance coverage for officers' liabilities.

Negatives

• The company has significant related party transactions, which could raise concerns about conflicts of interest.
• The company sold its subsidiaries, Kijima and Skynet, to entities owned by the CEO for nominal consideration for one of the subsidiaries, which could raise concerns about fairness.
• The company has a complex corporate structure with multiple related entities, which could make it difficult for investors to understand the business.

Risks

• Related party transactions could lead to potential conflicts of interest and may not always be on terms favorable to the company.
• Dependence on the CEO's relatives' involvement in Medical Corporations (MCs) in Japan creates a key-person risk.
• Changes in Japanese regulations regarding medical service corporations could impact the company's operations.
• The company's success depends on maintaining good relationships with the MCs and ensuring their compliance with the SBC brand standards.
• The company's reliance on key executives and their expertise poses a risk if they were to leave the company.

Future Outlook

The company is pursuing a long-term growth strategy aimed at expanding and stabilizing its business foundation by creating an environment that can better facilitate the establishment of new clinics by MCs.

Industry Context

The company operates in the medical and beauty industry, which is highly competitive and subject to changing consumer preferences and regulations. The company's success depends on its ability to adapt to these changes and maintain its competitive advantage.

Comparison to Industry Standards

• It is difficult to compare SBC Medical Group Holdings directly to industry standards due to its unique business model involving Medical Corporations (MCs) in Japan.
• However, the company's related party transactions are higher than industry standards.
• The company's corporate governance practices may not meet the standards of larger, more established companies.

Management Changes

Related Party Transactions

• The document details numerous related party transactions, including those with Medical Corporations (MCs) in Japan where relatives of the CEO are members.
• In January 2024, Legacy SBC acquired 353,600 shares of common stock of Waqoo, a related-party company listed on the Tokyo Stock Exchange, with a fair value of $5,565,938 through a share exchange agreement.
• The company sold its subsidiaries, Kijima and Skynet, to entities owned by the CEO for cash consideration of one Japanese Yen ($0) for Kijima and $446,460 for Skynet.

Stakeholder Impact

• Shareholders should be aware of the significant related party transactions and potential conflicts of interest.
• Employees may be affected by changes in management and corporate strategy.
• Customers may be impacted by changes in the company's services and operations.
• Suppliers and creditors should be aware of the company's financial condition and related party transactions.

Next Steps

• The company will continue to operate its business and execute its growth strategy.
• The company will continue to comply with SEC reporting requirements.
• The company will monitor and manage its related party transactions to ensure they are in the best interests of the company and its shareholders.

Key Dates

Keywords

related party transactions, executive employment agreements, director independence, Sarbanes-Oxley Act, medical corporations, SBC Medical Group, amendment, Form 10-K, merger, SPAC